Oncimmune Holdings plc announced the appointment of Dr. Annalisa Jenkins, MBBS, FRCP to the Company's Board as Non-Executive Director with immediate effect. Annalisa has approximately 25 years of experience in building and leading teams that advanced programs from scientific research through clinical development, regulatory approval and into healthcare systems globally. Until recently, Annalisa was Chief Executive Officer of Dimension Therapeutics. Prior to this, Dr. Jenkins served as executive vice president, Head of Global Research and Development, at Merck Serono where she also led global medical affairs and quality.